Literature DB >> 18393684

Human cord blood mononuclear cells decrease cytokines and inflammatory cells in acute myocardial infarction.

Robert J Henning1, Masood Shariff, Ujwala Eadula, Felipe Alvarado, Mark Vasko, Paul R Sanberg, Cyndy D Sanberg, Vincent Delostia.   

Abstract

We investigated whether human umbilical cord blood mononuclear cells (HUCBC), which contain hematopoietic and mesenchymal progenitor cells, can limit myocardial cytokine expression and inflammatory cell infiltration in acute myocardial infarction. We permanently ligated the left coronary artery of rats and injected into the myocardium either Isolyte or 4 x 10(6) HUCBC in Isolyte and measured myocardial cytokines with antibody arrays at 2, 6, 12, 24, and 72 hours after infarction. We then measured with flow cytometry myocardial macrophages, neutrophils and lymphocytes at 12, 24, and 72 hours after infarctions in rats treated with either intramyocardial Isolyte or 4 x 10(6) HUCBC. In the Isolyte-treated hearts, between 2 and 12 hours after myocardial infarction, tumor necrosis factor-alpha increased from 6.7 +/- 0.9% to 52.3 +/- 4.7%, monocyte chemoattract protein increased from 9.5 +/- 1.2% to 39.8 +/- 2.1%, fractalkine increased from 11 +/- 1.5% to 28.1 +/- 1.3%, ciliary neurotrophic factor increased from 12.1 +/- 0.02% to 25.9 +/- 1.1%, macrophage inflammatory protein increased from 10.3 +/- 1.5% to 23.9.0 +/- 1.4%, interferon-gamma increased from 8.7 +/- 0.4% to 26.0 +/- 1.6%, interleukin-1beta increased from 6.1 +/- 0.04% to 19.0 +/- 1.2%, and IL-4 increased from 5.9 +/- 0.03% to 15 +/- 1.5% (all p < 0.001 compared with controls). The concentrations of fractalkine remained significantly increased at 72 hours after acute infarction. In contrast, the myocardial concentrations of these cytokines did not significantly change in HUCBC treated hearts at 2, 6, 12, 24, or 72 hours after infarction. The percentage of neutrophils increased from 0.04 +/- 0.2%/50,000 heart cells in the controls to 5.3 +/- 1.2%/50,000 heart cells 12 hours after infarction in Isolyte-treated hearts but averaged only 1.3 +/- 0.7%/50,000 heart cells in HUCBC treated hearts (p < 0.02). Thereafter, the percentages of neutrophils rapidly decreased at 24 and at 72 hours after infarction and averaged 0.6 +/- 0.2%/50,000 heart cells at 72 hours after infarction in Isolyte-treated hearts in contrast to 0.2 +/- 0.1%/50,000 cells in HUCBC hearts (p < 0.05). Moreover, the percentages of neutrophils at 24 and 72 hours in HUCBC hearts were not significantly different from controls. At 24 hours post infarction, the percentage of CD3 and CD4 lymphocytes were 10.7 +/- 1.4% and 6.3 +/- 1.1%/50,000 cells in Isolyte hearts in comparison with only 4.9 +/- 0.8% and 2.9 +/- 0.5% in HUCBC hearts (p < 0.005 for Isolyte versus HUCBC). The percentage of CD11b macrophages was 2.8 +/- 0.3% in Isolyte hearts and 1.9 +/- 0.2% in HUCBC treated hearts (p < 0.05). At 72 hours after infarction, the percentage of CD3 and CD4 lymphocytes averaged 8.0 +/- 1.1% and 5.1 +/- 0.8%/50,000 heart cells in Isolyte hearts in comparison with only 4.1 +/- 0.5% and 2.3 +/- 0.4%/50,000 heart cells in the HUCBC treated infarctions (p < 0.005). Left ventricular infarct sizes in Isolyte-treated hearts at 72 hours post infarction averaged 15.7 +/- 1.4% of the left ventricular muscle area in contrast to HUCBC treated infarctions that averaged 6.9 +/- 1.4% of the left ventricular muscle area (p < 0.02). Moreover in rats followed for 2 months post infarction, the LV ejection fractions decreased to 65.4 +/- 1.9% and 69.1 +/- 1.9% at 1 and 2 months after infarction in Isolyte-treated hearts and were significantly different from HUCBC treated hearts that averaged 72.1 +/- 1.3% and 75.7 +/- 1.4% (both p < 0.02). The present experiments suggest that an important mechanism whereby HUCBC limit infarct size and improve left ventricular ejection fraction is by significantly limiting inflammatory cytokines and inflammatory cells in infarcted myocardium.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18393684     DOI: 10.1089/scd.2008.0023

Source DB:  PubMed          Journal:  Stem Cells Dev        ISSN: 1547-3287            Impact factor:   3.272


  17 in total

Review 1.  The hematopoietic system in the context of regenerative medicine.

Authors:  Christopher D Porada; Anthony J Atala; Graça Almeida-Porada
Journal:  Methods       Date:  2015-08-28       Impact factor: 3.608

2.  Translating G-CSF as an Adjunct Therapy to Stem Cell Transplantation for Stroke.

Authors:  Ike dela Peña; Cesar V Borlongan
Journal:  Transl Stroke Res       Date:  2015-12       Impact factor: 6.829

3.  The myocardium of fetuses with endocardial fibroelastosis contains fewer B and T lymphocytes than normal control myocardium.

Authors:  Nisha M Fernandes; Glenn P Taylor; Cedric Manlhiot; Brian W McCrindle; Michael Ho; Steven E S Miner; Adelle Atkinson; Edgar T Jaeggi; Lynne E Nield
Journal:  Pediatr Cardiol       Date:  2011-04-12       Impact factor: 1.655

Review 4.  Extracellular matrix roles during cardiac repair.

Authors:  Claude Jourdan-Lesaux; Jianhua Zhang; Merry L Lindsey
Journal:  Life Sci       Date:  2010-07-27       Impact factor: 5.037

Review 5.  Stem cells and G-CSF for treating neuroinflammation in traumatic brain injury: aging as a comorbidity factor.

Authors:  I Dela Peña; P R Sanberg; S Acosta; N Tajiri; S Z Lin; C V Borlongan
Journal:  J Neurosurg Sci       Date:  2014-05-20       Impact factor: 2.279

6.  TRPC1 Deficiency Impairs the Endothelial Progenitor Cell Function via Inhibition of Calmodulin/eNOS Pathway.

Authors:  Lai-Ling Du; Zhida Shen; Zhengwei Li; Xuewei Ye; Meiping Wu; Lihui Hong; Yanbo Zhao
Journal:  J Cardiovasc Transl Res       Date:  2018-03-12       Impact factor: 4.132

Review 7.  New Paradigms in Cell Therapy: Repeated Dosing, Intravenous Delivery, Immunomodulatory Actions, and New Cell Types.

Authors:  Marcin Wysoczynski; Abdur Khan; Roberto Bolli
Journal:  Circ Res       Date:  2018-07-06       Impact factor: 17.367

8.  Drug-like delivery methods of stem cells as biologics for stroke.

Authors:  Julian P Tuazon; Vanessa Castelli; Cesar V Borlongan
Journal:  Expert Opin Drug Deliv       Date:  2019-08-05       Impact factor: 6.648

9.  Inhibition of Janus activated kinase-3 protects against myocardial ischemia and reperfusion injury in mice.

Authors:  Young-Bin Oh; Min Ahn; Sang-Myeong Lee; Hyoung-Won Koh; Sun-Hwa Lee; Suhn Hee Kim; Byung-Hyun Park
Journal:  Exp Mol Med       Date:  2013-05-17       Impact factor: 8.718

Review 10.  The role of antioxidation and immunomodulation in postnatal multipotent stem cell-mediated cardiac repair.

Authors:  Arman Saparov; Chien-Wen Chen; Sarah A Beckman; Yadong Wang; Johnny Huard
Journal:  Int J Mol Sci       Date:  2013-08-06       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.